VYNE Therapeutics Inc. carries no debt; cash flow comfortably covers obligations.

VYNE Therapeutics Inc.'s free cash flow has increased -2.83% from $-34.09M last year to $-33.12M, signaling increasing performance

VYNE Therapeutics Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

VYNE Therapeutics Inc.'s debt has decreased relative to shareholder equity from 0.00 last year to 0.00 today, signaling strengthened financials

VYNE Therapeutics Inc. has negative EBITDA, making leverage ratio unreliable

VYNE Therapeutics Inc. carries no debt; interest obligations are fully covered.

VYNE Therapeutics Inc.'s profit margin has increased (-40.56%) in the last year from -7.95K% to -4.73K%, signaling increasing performance

VYNE Therapeutics Inc.'s short-term assets of $30.01M exceed its short-term liabilities of $2.40M

VYNE Therapeutics Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

VYNE Therapeutics Inc.'s return on equity of -69.57%, is lower than 15.00%, indicating bad performance

VYNE Therapeutics Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

VYNE Therapeutics Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

VYNE Therapeutics Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

VYNE Therapeutics Inc. has negative free cash flow, indicating cash burn

VYNE Therapeutics Inc.'s yearly earnings has increased -33.52% since last year from $-39.83M to $-26.48M, signaling increasing performance

VYNE Therapeutics Inc.'s yearly revenue has increased 13.77% since last year from $501.00K to $570.00K, signaling increasing performance

ROIC -98.91% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

VYNE Therapeutics Inc.'s 3-year revenue CAGR of 6.12% is positive, indicating growing revenue over the past 3 years

VYNE Therapeutics Inc. had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance

VYNE Therapeutics Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

VYNE Therapeutics Inc. has insufficient data to evaluate this check.

VYNE Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

VYNE Therapeutics Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

VYNE Therapeutics Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

VYNE Therapeutics Inc. is overvalued relative to its fair value price of -6.18 based on Earnings Fair Value model

VYNE Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

VYNE Therapeutics Inc. has a price-to-book ratio of 1.23x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

VYNE Therapeutics Inc. has a price-to-sales ratio of 67.08x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue